Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
IV

NASDAQ · IVA

Inventiva S.A.

Healthcare · Biotechnology

$4.02

Down-$0.12 (-2.90%)

Updated Sep 12, 2026, 8:06 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
233.4M
P/E ratio
-1.32
Dividend yield
0.00%
52-week range
$3.35 – $7.98
Volume
1.71M
Avg. volume
247.07K

Price performance

IVA price history

1M range · 0 trading sessions · Daily adjusted prices

IVA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest IVA news

The latest Smart Investors Daily articles mentioning IVA.

Stock researchCompany · Overview

IVA research

Overview

Company profile and research snapshot.

Company profile

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.33
Implied upside
—
Analysts
—
IVA recent ratings
DateFirmRatingTarget
Jul 9, 2026KBC SECURITIESBuy—
Jun 30, 2026TD COWENBuy—
Jun 28, 2026PORTZAMPARC BNP PARIBASBuy—
Jun 23, 2026PIPER SANDLER COMPANIESOverweight—
May 26, 2026GUGGENHEIM SECURITIES LLCBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Inventiva to Present Multiple Abstracts at Paris MASH 2026

Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and cardiac profile relative to TZDs and dual PPARα/γ agonists Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clin

Yahoo · Sep 2, 2026

Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference participation and timing of H1 2026 financial results update Daix (France), New York (New York, United States), September 2nd, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of

Yahoo · Aug 31, 2026

Chris Benecchi Named Inventiva’s New Chief Operating Officer

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By